CLEVELAND, Nov. 30, 2011 /PRNewswire/ -- University Hospitals Case Medical Center researchers could still be close to giving heart attack patients a second chance…just not as they originally thought.
The "LateTIME" trial was a study of adult stem cells (autologous) harnessed from bone marrow that were believed to have the ability to improve heart function after an attack if injected into the heart within two weeks of the attack.
Results were released this week at the 2011 American Heart Association (AHA) Scientific Sessions conference and were subsequently published this week in Journal of the American Medical Association (JAMA). The results have shown the injections within that timeframe were not favorable, but the concept showed great promise, according to an accompanying JAMA editorial that assessed the trial.
Despite the initial low return, the therapy had effectiveness for some of the patients that were enrolled in the trial as demonstrated by improved heart function post stem cell injection.
Both UH Case Medical Center's Drs. Dan Simon and Marco Costa, co-investigators in the LateTIME study, are currently participating in a similar trial, "TIME" that already has reduced the time between attack and stem cell injection.
The pair is optimistic the time variable adjustment in the new trial will lend favorable outcomes.
"We have reason to believe, as supported by data, that an adjusted injection timeframe could yield stronger results and support for stem cell injections rebuilding damaged heart muscle and function," said Dr. Simon, Chief, Cardiovascular Medicine at UH Case Medical Center and the Herman K. Hellerstein Professor of Cardiovascular Research, Case Western Reserve University School of Medicine.
"The results were not positive, but if you put it into perspective, the foundation or blueprint for success was discovered and that could certainly lead to advanced treatment options for these patients,
|SOURCE University Hospitals Case Medical Center|
Copyright©2010 PR Newswire.
All rights reserved